dc.contributor.author | Meric-Bernstam, F | |
dc.contributor.author | Makker, V | |
dc.contributor.author | Oaknin, A | |
dc.contributor.author | Oh, D-Y | |
dc.contributor.author | Banerjee, S | |
dc.contributor.author | González-Martín, A | |
dc.contributor.author | Jung, KH | |
dc.contributor.author | Ługowska, I | |
dc.contributor.author | Manso, L | |
dc.contributor.author | Manzano, A | |
dc.contributor.author | Melichar, B | |
dc.contributor.author | Siena, S | |
dc.contributor.author | Stroyakovskiy, D | |
dc.contributor.author | Fielding, A | |
dc.contributor.author | Ma, Y | |
dc.contributor.author | Puvvada, S | |
dc.contributor.author | Shire, N | |
dc.contributor.author | Lee, J-Y | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2024-01-17T13:42:41Z | |
dc.date.available | 2024-01-17T13:42:41Z | |
dc.date.issued | 2024-01-01 | |
dc.identifier.citation | Journal of Clinical Oncology, 2024, 42 (1), pp. 47 - 58 | |
dc.identifier.issn | 0732-183X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6114 | |
dc.identifier.eissn | 1527-7755 | |
dc.identifier.eissn | 1527-7755 | |
dc.identifier.doi | 10.1200/JCO.23.02005 | |
dc.identifier.doi | 10.1200/JCO.23.02005 | |
dc.description.abstract | PURPOSE: Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non-small-cell lung cancer. Treatments are limited for other HER2-expressing solid tumors. METHODS: This open-label phase II study evaluated T-DXd (5.4 mg/kg once every 3 weeks) for HER2-expressing (immunohistochemistry [IHC] 3+/2+ by local or central testing) locally advanced or metastatic disease after ≥1 systemic treatment or without alternative treatments. The primary end point was investigator-assessed confirmed objective response rate (ORR). Secondary end points included safety, duration of response, progression-free survival (PFS), and overall survival (OS). RESULTS: At primary analysis, 267 patients received treatment across seven tumor cohorts: endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and other. The median follow-up was 12.75 months. In all patients, the ORR was 37.1% (n = 99; [95% CI, 31.3 to 43.2]), with responses in all cohorts; the median DOR was 11.3 months (95% CI, 9.6 to 17.8); the median PFS was 6.9 months (95% CI, 5.6 to 8.0); and the median OS was 13.4 months (95% CI, 11.9 to 15.5). In patients with central HER2 IHC 3+ expression (n = 75), the ORR was 61.3% (95% CI, 49.4 to 72.4), the median DOR was 22.1 months (95% CI, 9.6 to not reached), the median PFS was 11.9 months (95% CI, 8.2 to 13.0), and the median OS was 21.1 months (95% CI, 15.3 to 29.6). Grade ≥3 drug-related adverse events were observed in 40.8% of patients; 10.5% experienced adjudicated drug-related interstitial lung disease (ILD), with three deaths. CONCLUSION: Our study demonstrates durable clinical benefit, meaningful survival outcomes, and safety consistent with the known profile (including ILD) in pretreated patients with HER2-expressing tumors receiving T-DXd. Greatest benefit was observed for the IHC 3+ population. These data support the potential role of T-DXd as a tumor-agnostic therapy for patients with HER2-expressing solid tumors. | |
dc.format | Print-Electronic | |
dc.format.extent | 47 - 58 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | |
dc.relation.ispartof | Journal of Clinical Oncology | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Humans | |
dc.subject | Female | |
dc.subject | Carcinoma, Non-Small-Cell Lung | |
dc.subject | Receptor, ErbB-2 | |
dc.subject | Antibodies, Monoclonal, Humanized | |
dc.subject | Lung Neoplasms | |
dc.subject | Trastuzumab | |
dc.subject | Immunoconjugates | |
dc.subject | Lung Diseases, Interstitial | |
dc.subject | Breast Neoplasms | |
dc.title | Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-10-12 | |
dc.date.updated | 2024-01-17T13:37:21Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1200/JCO.23.02005 | |
rioxxterms.licenseref.startdate | 2024-01-01 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/37870536 | |
pubs.issue | 1 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1200/jco.23.02005 | |
pubs.volume | 42 | |
dc.contributor.icrauthor | Banerjee, Susana | |
icr.provenance | Deposited by Mr Arek Surman on 2024-01-17. Deposit type is initial. No. of files: 1. Files: meric-bernstam-et-al-2023-efficacy-and-safety-of-trastuzumab-deruxtecan-in-patients-with-her2-expressing-solid-tumors.pdf | |